P
Paul Anthony Ellis
Researcher at Sarah Cannon Research Institute
Publications - 10
Citations - 334
Paul Anthony Ellis is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Trastuzumab emtansine & Trastuzumab. The author has an hindex of 8, co-authored 10 publications receiving 244 citations.
Papers
More filters
Journal ArticleDOI
Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Paul Anthony Ellis,Carlos H. Barrios,Wolfgang Eiermann,Masakazu Toi,Young-Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Alexander Strasak,Monika Patre,Edith A. Perez +12 more
TL;DR: Treatment with T-DM1 or with P + H + docetaxel or both has shown statistically significant increases in progression-free survival (PFS) and overall survival (OS) in phase II and III studies.
Journal ArticleDOI
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
Filippo Montemurro,Paul Anthony Ellis,Antonio Anton,Rachel Wuerstlein,Suzette Delaloge,Jacques Bonneterre,N Quenel-Tueux,Sabine C. Linn,Natsumi Irahara,Margarita Donica,Nicolas Lindegger,Carlos H. Barrios +11 more
TL;DR: Results are consistent with prior randomised studies, thereby supporting T-DM1 as safe, tolerable and efficacious treatment for patients with previously treated HER2-positive advanced BC.
Journal ArticleDOI
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
Edith A. Perez,Carlos H. Barrios,Wolfgang Eiermann,Masakazu Toi,Young-Hyuck Im,Pierfranco Conte,Miguel Martín,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Jennifer A. Petersen,Sanne de Haas,Silke Hoersch,Monika Patre,Paul Anthony Ellis +14 more
TL;DR: The final descriptive overall survival (OS) analysis, updated safety data, and additional patient‐reported outcomes and biomarker analyses are reported.
Journal ArticleDOI
MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
TL;DR: The first phase III study to evaluate the combination of a targeted antibody and an ADC for first-line MBC has the potential to establish a new treatment paradigm by optimizing efficacy while minimizing toxicity.
Journal ArticleDOI
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A. Perez,Sanne de Haas,Wolfgang Eiermann,Carlos H. Barrios,Masakazu Toi,Young Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Sven Stanzel,Monika Patre,Paul Anthony Ellis +13 more
TL;DR: In MARIANNE, biomarkers related to the HER2 pathway did not have predictive value for PFS when comparing T-DM1 (with or without pertuzumab) with trastuzuab plus taxane, however, HER2 mRNA level and PIK3CA mutation status showed prognostic value.